The news was a major tonic for Merck, which is chasing close behind Opdivo with its rival PD-1 drug Keytruda (pemtruzumab) across a number of cancer types. Opdivo has established a clear lead so ...

Bristol-Myers Squibb's (BMS) Opdivo, the first in a new generation on immunotherapy cancer drugs approved to treat non-small cell lung cancer (NSCLC) has been rejected by NICE in draft guidance.

Different parts of Medicare can provide coverage for cancer ... Opdivo infusions that a person gets as an outpatient in a health center or doctor’s clinic. Medicare Part D covers prescription ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer. Opdivo (nivolumab) plus Yervoy (ipilimumab) improved ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...